The objective of this document is to synthesize national and international evidence and promising practices in HIV/TB/HCV/STBBI (HIV/Tuberculosis/Hepatitis C/Sexually Transmitted and Blood-Borne Infections) related prevention, treatment and care programming and delivery models in relation to newcomer health and social well-being.
Publication Categories
Archives(2)
Combination Prevention(26)
Community and Health Systems Strengthening(9)
HIV and Co-infections(4)
Key Populations and Vulnerable Groups(19)
Public Policy and Global Engagement(10)
Reproductive, Maternal, Newborn and Child Health (RMNCH)(1)
Social Determinants of Health(15)
Toolkits(7)
Twinning(6)
Sort by:
Literature review
Related Content:
Updated Training Manual for Treatment Advocates: Hepatitis C Virus and Coinfection with HIV [Treatment Action Group - TAG] February 1, 2018 The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and…
NGO Observer Statement - HIV in Prisons and Closed Settings March 10, 2016 UNAIDS PCB - Statement Agenda Item: 6 HIV in Prisons and Closed Settings 27 October 2015 - 37th UNAIDS PCB Meeting, Geneva, Switzerland Before I begin I would like to…
Canada’s hidden HIV epidemic December 7, 2018 By Laurie Edmiston, CATIEEarlier this year, I witnessed a profound historic moment at the International AIDS Conference in Amsterdam. Dr. Alison Rodger, a leading HIV researcher in the United Kingdom,…
Know Your Rights: Tuberculosis Prevention, Diagnosis, and Treatment Guide [Treatment Action Group - TAG] January 31, 2018 This guide is for people who have tuberculosis (TB), people who are at risk for it, and the people who take care of them. It explains what global standards are…
[MPP Statement] The Medicines Patent Pool Publishes 2017 Prioritization Report Targeting New HIV and Hepatitis C Medicines for In-licensing March 1, 2017 The Medicines Patent Pool released its 2017 prioritization report today selecting five HIV and two hepatitis C compounds for potential licensing agreements. The annual medicines priority report, traditionally reviewing MPP’s…
Closing the Gap? Cut the Crap! December 4, 2018 New Research Priorities from the US National Institutes of Health (NIH) Restricts Prevention OptionsBy Marc-André LeBlanc, Founding member of IRMA International Rectal Microbicide Advocates (IRMA) and our many partners and…